Reverse regulation of soluble receptor for advanced glycation end products and proinflammatory factor resistin and S100A12 in Kawasaki disease

Arthritis Research and Therapy

Volumn 14, Issue 6, 2012, Pages

  Qi, Yanqi ^a   Gong, Fangqi ^a   Zhang, Qing ^a   Xie, Chunhong ^a   Wang, Wei ^a   Fu, Songling ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT RECEPTOR; CALCIUM BINDING PROTEIN; DIPYRIDAMOLE; IMMUNOGLOBULIN; PROTEIN S100A12; RESISTIN; UNCLASSIFIED DRUG; WARFARIN; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; IMMUNOLOGIC FACTOR; PROTEIN S 100; S100A12 PROTEIN, HUMAN;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION COEFFICIENT; DISEASE COURSE; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; SCHOOL CHILD; TREATMENT RESPONSE; ACUTE DISEASE; ANALYSIS OF VARIANCE; BLOOD; TREATMENT OUTCOME;

ACUTE DISEASE; ANALYSIS OF VARIANCE; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; RECEPTORS, IMMUNOLOGIC; RESISTIN; S100 PROTEINS; TREATMENT OUTCOME;

EID: 84869215552     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4094     Document Type: Article

References (24)

1. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MCLS) prevailing in Japan. Pediatrics 1974, 54:271-276.
2. Suzuki A, Kamiya T, Arakaki Y, Kinoshita Y, Kimura K. Fate of coronary arterial aneurysms in Kawasaki disease. Am J Cardiol 1994, 74:822-824. 10.1016/0002-9149(94)90446-4, 7942561.
3. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003, 300:472-476. 10.1016/S0006-291X(02)02841-3, 12504108.
4. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001, 50:2199-2202. 10.2337/diabetes.50.10.2199, 11574398.
5. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005, 174:5789-5795.
6. Lago F, Dieguez C, Gomez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007, 18:313-325. 10.1016/j.cytogfr.2007.04.007, 17507280.
7. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005, 334:1092-1101. 10.1016/j.bbrc.2005.06.202, 16039994.
8. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6:772-783. 10.1038/nri1937, 16998510.
9. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003, 108:736-740. 10.1161/01.CIR.0000084503.91330.49, 12874180.
10. Li Y, Wang Y, Li Q, Chen Y, Sun SZ, Zhang WD, Jia Q. Effect of resistin on vascular endothelium secretion dysfunction in rats. Endothelium 2007, 14:207-214.
11. Pischon T, Bamberger CM, Kratzsch J, Zyriax BC, Algenstaedt P, Boeing H, Windler E. Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005, 13:1764-1771. 10.1038/oby.2005.215, 16286524.
12. Burnett MS, Lee CW, Kinnaird TD, Stabile E, Durrani S, Dullum MK, Devaney JM, Fishman C, Stamou S, Canos D, Zbinden S, Clavijo LC, Jang GJ, Andrews JA, Zhu J, Epstein SE. The potential role of resistin in atherogenesis. Atherosclerosis 2005, 182:241-248. 10.1016/j.atherosclerosis.2005.02.014, 16159596.
13. Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol 2012, 165:622-632. 10.1111/j.1476-5381.2011.01369.x, 21545576.
14. Lee SE, Kim HS. Human resistin in cardiovascular disease. J Smooth Muscle Res 2012, 48:27-35. 10.1540/jsmr.48.27, 22504487.
15. Guignard F, Mauel J, Markert M. Identification and characterization of a novel human neutrophil protein related to the S100 family. Biochem J 1995, 309:395-401. 1135745, 7626002.
16. Foell D, Ichida F, Vogl T, Yu X, Chen R, Miyawaki T, Sorg C, Roth J. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 2003, 361:1270-1272. 10.1016/S0140-6736(03)12986-8, 12699958.
17. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007, 81:28-37.
18. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003, 370:1097-1109. 10.1042/BJ20021371, 1223244, 12495433.
19. Fu S, Gong F, Xie C, Zhu W, Wang W, Shen H, Tang Y. S100A12 on circulating endothelial cells surface in children with Kawasaki disease. Pediatr Res 2010, 68:165-168. 10.1203/PDR.0b013e3181e67ce8, 20461025.
20. Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, Ishii M, Harada K, . Kawasaki Disease Research Committee Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 2005, 47:232-234. 10.1111/j.1442-200x.2005.02033.x, 15771703, Kawasaki Disease Research Committee.
21. Manlhiot C, Millar K, Golding F, McCrindle BW. Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. Pediatr Cardiol 2009, 31:242-249.
22. Catalano M, Cortelazzo A, Santi R, Contino L, Demicheli M, Yilmaz Y, Zorzetto M, Campo I, Lanati N, Emanuele E. The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease. Clin Biochem 2008, 41:981-985. 10.1016/j.clinbiochem.2008.05.007, 18538667.
23. Kemmotsu Y, Saji T, Kusunoki N, Tanaka N, Nishimura C, Ishiguro A, Kawai S. Serum adipokine profiles in Kawasaki disease. Mod Rheumatol 2012, 22:66-72. 10.1007/s10165-011-0468-x, 21633913.
24. Nozue H, Imai H, Saitoh H, Aoki T, Ichikawa K, Kamoda T. Serum resistin concentrations in children with Kawasaki disease. Inflamm Res 2010, 59:915-920. 10.1007/s00011-010-0202-8, 20422438.